GoldenGolden
Advanced Search
Fusion Pharmaceuticals

Fusion Pharmaceuticals

Biotechnology company using alpha particle emitting medical isotopes in targeted radiotherapy for cancer.

Fusion Pharmaceuticals is a McMaster University startup company based at the McMaster Innovation Park. The biotech company uses alpha particle emitting medical isotopes in targeted radiotherapy for cancer.

Fusion is a spinout from the Centre for Probe Development and Commercialization (CPDC). Founder, CEO and Director, Dr. John Valliant, Ph.D. of Fusion Pharmaceuticals also founded the CPDC in 2008. Dr. Valliant is a Canada Research Chair in Medical Isotopes and Molecular Imaging Probes and a Professor of Chemistry and Chemical Biology at McMaster University. CSO Dr. Eric Burak, Ph.D. previously worked at CPDC, Theracos, Rib-X Pharmaceuticals and Guilford Pharmaceuticals.

Technology

Alpha particles, emitted by certain medical isotopes, are highly energetic and deposit their energy over distances as short as the width of a single cell. Alpha emitting isotopes delivered to cancer cells kill tumor cells through mechanisms such as double stranded DNA breaks.

Fusion is using molecules such as antibodies, with potent alpha emitting isotopes to target cancer precisely and induce cancer cell death. The short distance that alpha particles travel enables them to localize radiation to the tumor. Fusion’s protein discovery platform is being used to screen for new targeting molecules to localize alpha medical isotope treatments. Fusion’s lead program FPX-01 is an antibody-targeting radiotherapy which targets IGF-1R, a biomarker of resistance present in almost all types of cancer that are refractory to treatment. The technology delivers actinium-225 to tumor cells.

Medical isotopes that are not specifically bound to cancer cells are excreted due to Fusion's proprietary Fast-ClearTM Technology Platform. The Fast-ClearTM Linker is a "connector" between a molecule and a medical isotope that is engineered to clear more medical isotope at a rate that is faster compared to commercial technologies. Fusion's technology is aimed at expanding the therapeutic window and potentially allowing a more safe and effective therapy. The excretion route and kinetics for different targeting molecule can be optimized with Fusion's library of proprietary linkers. The company is applying their technology to a range of molecules such as antibodies and small molecules.

Investments

Series A financing of $25 million was led by Johnson & Johnson Innovation in 2017 and included investments from HealthCap, TPG Biotech, Genesys Capital and FACIT. In April, 2019 the company secured US$105 million in financing, which at the time was one of the largest single private investments in Canadian biotech history.

Timeline

May 6, 2021
Fusion Pharmaceuticals announces clinical collaboration with Merck to evaluate Fusion's Targeted Alpha Therapy (TAT) in combination with Merck's KEYTRUDA® (pembrolizumab) in patients with solid tumors
March 2, 2021
Fusion Pharmaceutical announces that it has entered into an asset purchase agreement to acquire Ipsen's intellectual property and assets related to IPN-1087.
April 2019
Fusion Pharmaceuticals raises a $105,000,000 series B round from Adams Street Partners, Genesys Capital, Johnson & Johnson, Johnson & Johnson Innovation – JJDC, OrbiMed, Perceptive Advisors, Pivotal bioVenture Partners, Rock Springs Capital, Seroba Life Sciences, TPG Biotech and Varian, Inc..
September 2017
Fusion Pharmaceuticals raises a $21,000,000 series A round from Adams Street Partners, Seroba Life Sciences and Varian Medical Systems.
February 23, 2017
Fusion Pharmaceuticals raises a $25,000,000 series A round.
2015
Fusion Pharmaceuticals was founded by John Valliant.

Funding rounds

People

Name
Role
LinkedIn

Eric Burak, Ph.D.

CSO

John F. Valliant, Ph.D.

Founder, CEO, Director

Further reading

Title
Author
Link
Type
Date

Documentaries, videos and podcasts

Title
Date
Link

Companies

Company
CEO
Location
Products/Services

News

Title
Author
Date
Publisher
Description
BioSpace
June 7, 2021
BioSpace
Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), today announced the appointment of Isabelle Dussault, Ph.D. as senior vice president, research.
Fusion Pharmaceuticals Inc.
June 7, 2021
www.prnewswire.com:443
/PRNewswire/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as...
May 11, 2021
BioSpace
Fusion Pharmaceuticals Announces First Quarter 2021 Financial Results and Business Update - read this article along with other careers information, tips and advice on BioSpace
Fusion Pharmaceuticals Inc.
May 11, 2021
www.prnewswire.com:443
/PRNewswire/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as...
BioSpace
May 6, 2021
BioSpace
Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced that it has entered into a clinical trial collaboration with a subsidiary of Merck (known as MSD outside the U.S. and Canada)
Fusion Pharmaceuticals Inc.
April 14, 2021
www.prnewswire.com:443
/PRNewswire/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as...
Fusion Pharmaceuticals Inc.
December 10, 2020
www.prnewswire.com:443
/PRNewswire/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as...
Fusion Pharmaceuticals Inc.
November 12, 2020
www.prnewswire.com:443
/PRNewswire/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as...

References

Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.